Virtuix Signs Strategic Partnership with Sirica Therapeutics to Advance AI-Driven Autism Therapy

About this update from Virtuix Holdings Inc.

Initial Deployment Brings Omni One Systems to Sirica's First Bay Area Treatment Center Collaboration Builds on Rutgers University Research and Advances Sirica's Plan to Establish 100 Autism Treatment Centers Nationwide AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) -- Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced a strategic partnership with Sirica Therapeutics to deploy its Omni One platform for immersive autism therapy applications. As part of the collaboration, Virtuix has sold and shipped the first two Omni One systems to Sirica's treatment center in the San Francisco Bay Area. The companies intend to use movement-centered virtual reality and AI-assisted therapeutic experiences to enhance engagement and treatment outcomes for children with autism and related disorders. Sirica has announced plans to establish approximately 100 Sirica Centers across the United States, creating a nationwide network of specialized autism treatment facilities. The partnership represents another important milestone in Virtuix's expansion into healthcare applications following its recently announced research collaboration with Rutgers University to explore AI-assisted neurodivergent therapy using the Omni One platform and its collaboration with Florida Gulf Coast University using Omni One for neurological rehabilitation. These initiatives advance Virtuix's strategy to extend its immersive simulation platform into clinical environments where movement-based technologies may enhance patient engagement and therapy efficacy. "We believe AI-driven, full-body immersive simulation has the potential to transform how behavioral therapies are delivered," said Jan Goetgeluk, Founder and CEO of Virtuix. "Our collaboration with Sirica Therapeutics represents an exciting step toward bringing movement-centered XR into real-world clinical settings. Combined with our ongoing research at Rutgers University and Florida Gulf Coast University, this collaboration reinforces our commitment to advancing innovative healthcare applications for Omni One." "We are excited to partner with Virtuix to advance movement-based autism therapy through AI and immersive virtual reality," said Dr. Uli K. Chettipally, Founder and CEO of Sirica Therapeutics. "At Sirica, our vision is to create a new model of care for autism and neurodiversity. Our Cognitive Sensory Motor (COSMO) therapy harnesses purposeful movement, sensory engagement, and cognitive challenge to improve quality of life outcomes. We look forward to partnering with Virtuix as we expand our network of Sirica Centers nationwide."

View stock analysis, news, and events for Virtuix Holdings Inc.